LifeSci Capital initiated coverage of Protara Therapeutics (TARA) with an Outperform rating and $22 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARA:
- Protara Therapeutics’ TARA-002 Shows Promising Efficacy and Safety in HR-NMIBC, Earning Buy Rating
- Protara Therapeutics Reports Progress and Financial Results
- Protara Therapeutics reports Q4 EPS (48c) vs (90c) last year
- TARA Earnings this Week: How Will it Perform?
- Protara Therapeutics Outlines 2025 Milestones After Fundraising
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue